Training improves glaucoma-induced visual field defects

Article

Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial.

Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial published in JAMA Ophthalmology. A new rehabilitation treatment option for such patients may involve behavioural computer-based, online-controlled vision training.

Behavioural vision training has been shown to improve visual fields in hemianopia and optic nerve damage. For this prospective, double-blind, randomized, placebo-controlled clinical trial, researchers gathered a volunteer sample of patients with glaucoma in an ambulatory care and home training setting.

Patients were a mean age of 61.7 years, all with stable visual fields and well-controlled IOPs. Interventions consisted of computer-based vision restoration training for glaucoma (n = 15) or visual discrimination placebo training in the intact visual field (n = 15).

Vision restoration training brought about significant detection accuracy gains in high-resolution perimetry (P = 0.007) not found with white-on-white or blue-on-yellow perimetry. In addition, Pre- to post-differences after training were greater compared with placebo in all perimetry tests (P = 0.02 for high-resolution perimetry; P = 0.04 for both white-on-white and for blue-on-yellow). All results were independent of eye movements.

Vision restoration training for glaucoma but not placebo led to a faster reaction time (P = 0.009). Patients' vision-related quality of life was unaffected, but patients' health-related quality-of-life mental health domain increased in both the vision restoration training and placebo groups.

To view the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.